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ABSTRACT
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved
for treatment of Crohn’s Disease (CD) since the end of 2016. This nationwide noninterventional, retro-
spective chart review explored real-life data in patients receiving UST to provide guidance in UST
treatment in the era of increasing prevalence of CD.
Methods: The study assessed UST treatment patterns such as dosing frequency, concomitant medica-
tion and persistence in 48CD patients commencing UST therapy in 12 Finnish hospitals during 2017.
Clinical remission and response rates were explored using a modified Harvey–Bradshaw index (mHBI)
and endoscopic response via the simple endoscopic score for Crohn’s disease (SES-CD) as proportions
of patients at week 16 and at the end of follow-up.
Results: Forty patients (83%) continued UST-treatment at the end of follow-up. At week 16, clinical
response and endoscopic healing was observed, where data were available; mHBI decreased from 9 to
3 (p¼ .0001) and SES-CD from 12 to 3 (p¼ .009). Clinical benefit was achieved by 83% (19/23) at week
16 and by 76% (16/21) at the end of follow-up. The proportion of patients using corticosteroids
decreased from 48% to 25% at week 16 and to 13% at the end of the follow-up.
Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endo-
scopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in
patients with highly treatment refractory and long-standing CD was observed.
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Introduction
Crohn’s Disease (CD) is a chronic, incurable inflammatory
bowel disease (IBD) that can lead to irreversible damage of
the intestine and disability. Current therapies aim for a deep
and prolonged remission with the goal of preventing compli-
cations and halting the progressive course of disease [1]. The
treatment of CD with thiopurines and methotrexate is often
insufficient or limited by adverse effects [2]. The use of
monoclonal antibody against TNF has improved treatment
outcomes remarkably [3], but still a considerable number of
patients either fail to respond or lose response over time [4].
For these patients with refractory disease, medical agents
with other modes of action than TNF-inhibition provide new
and promising treatment options.
Ustekinumab (UST) is a fully human monoclonal IgG1k
antibody directed against the p40 subunit of interleukin (IL)-
12 and IL-23. The treatment with UST has been reported to
induce and maintain remission in patients with CD in rando-
mised controlled phase II (CERTIFI) and III clinical trials (UNITI
1 and 2, IM-UNITI) [5–8]. The efficacy of UST has been proven
in both TNF-inhibitor naïve and in TNF-inhibitor experienced
patients, with a better response in bio-naïve patients [5].
At the end of 2016 UST was approved by the U.S. Food
and Drug Administration (FDA) and the European Medicines
Agency (EMA) for the treatment of moderate or severe CD
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[9,10], using intravenous induction and subcutaneous main-
tenance with either every 8- (for nonresponders) or every
12-week dosing (EMEA/H/C958/X/49) [9]. The dosing regimen
with one intravenous dose and subsequent subcutaneous
dosing differs from the dosing of other biologics used for
the treatment of CD. This dosing regimen is based on large
clinical trials with highly selected patient populations [5].
Prior to UST approval for CD patients, access to UST outside
of clinical trials was limited only to compassionate use pro-
grams. Therefore, in previously published open-label studies,
only subcutaneous administration of UST, available due to its
previous approval for the treatment of psoriasis, with a var-
iety of different dosing regimens was used [11–18]. Only
recently, a prospective real-life study of intravenous induced
UST-treated patients was published [19].
Although the efficacy and safety of UST has been shown
in clinical trials, more knowledge on patient outcomes with
the approved dosing regimen [20] in real-life settings is
needed to help guide clinicians treating CD patients. In cur-
rent study, we describe our experience with UST in a real-life
nationwide cohort of CD patients in Finland.
Patients and methods
Study population and data collection
The FINUSTE study, including data from 12 Finnish hospitals,
was a nationwide retrospective observational, noninterven-
tional patient chart review on adults (18 years) diagnosed
with CD (International Classification of Diseases, 10th revi-
sion; ICD-10: K50 all subclasses), and who initiated intraven-
ous UST treatment during 2017. The data were collected
from health records in an electronic standardized health
questionnaire by the local gastroenterologist at each hos-
pital. UST treated patients were included regardless of their
previous treatments with conventional therapies or biological
agents. Patients diagnosed with ulcerative colitis or IBD-
unclassified (ICD-10: K51 all subclasses) or other specified
noninfective gastroenteritis and colitis (ICD-10: K52 all sub-
classes) were excluded.
Data were collected at baseline, at week 16 (±4 weeks)
and at the end of follow-up (April 30, 2018). Collected base-
line data on clinical characteristics and demographics were:
age, sex, smoking status, height, weight, diagnosis, year of
diagnosis, history of bowel surgery, comorbidities (psoriasis,
ankylosing spondylitis, hidradenitis suppurativa), age at diag-
nosis, disease location and behaviour according to the
Montreal classification, and clinically relevant medication for
CD. As a part of the clinical routine follow-up haemoglobin,
leukocytes, platelets, albumin, serum C-reactive protein (CRP)
and faecal calprotectin (fCal) were assessed and these data
were collected retrospectively at baseline, around week 16
and at the end of follow-up. For fCal values considered as
normal were <100 lg/g of stool [21]. If the investigators
encountered notations related to adverse events possibly,
probably or very likely attributed to UST while reviewing the
patient charts within the scope of the information required
by the protocol, they were instructed to report these
separately and directly to Janssen-Cilag Oy due to the phar-
macovigilance obligations of drug manufacturers.
Outcome measures
The analyzed UST treatment patterns included doses at
induction and dosing interval during the maintenance phase
of treatment. The proportion of patients discontinuing UST
treatment, the reason for discontinuing and the use of con-
comitant drugs were determined. The percentage of patients
without concurrent corticosteroid medication and the per-
centage of patients using UST monotherapy was calculated.
Short-term clinical outcome was evaluated using clinical
and endoscopic disease activity scores. For assessment of
clinical disease activity, a modified Harvey–Bradshaw index
(mHBI) excluding findings in abdominal palpation–variable
was used [22], as omitting the abdominal palpation has pre-
viously shown not to make any difference [23]. Clinical remis-
sion was defined as mHBI 4 points and clinical response as
an mHBI reduction of 3 points from baseline [24]. Clinical
benefit was determined as the proportion of patients in
remission and/or with response. The simple endoscopic score
for Crohn’s disease (SES-CD) served for assessment of endo-
scopic CD activity [25].
Statistical analysis
The descriptive findings were reported as mean and standard
deviation (SD) for continuous variables, median and inter-
quartile range (IQR) for laboratory measures and clinical out-
comes and as proportions for categorical variables. In
addition, changes over time in fCal, CRP, mHBI and SES-CD
were described. The results were reported for patients still
using UST at each time point. In the analyses, UST use was
considered to continue if the date of UST discontinuance
was less than eight weeks from the assessment time point.
The significance of the observed changes was tested with
the test of proportions for categorical variables and Wilcoxon
matched-pairs signed-rank test for changes in clinical out-
comes and laboratory measurements. Results having a
p-value lower than .05 were considered statistically signifi-
cant. All analyses were performed with Stata MP 14 statistical
software (StataCorp 2015, Stata Statistical Software: Release
14. College Station, TX: StataCorp LP).
Ethical considerations
The study was registered in the European Union electronic
Register of Post-Authorization Studies (EU PAS Register,
EUPAS 24728). The study protocol was reviewed by the
ethics committee of Tampere University Hospital (No:
R18055) and approved by the local register holders.
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Results
Patient characteristics
Fifteen Finnish hospitals identified as centers using intravenous
UST induction for CD treatment were invited to participate in
this study. Of these, 12 hospitals participated, including three
university and nine central hospitals with a geographically rep-
resentative coverage of Finland (Figure 1). The study popula-
tion consisted of 48 patients. Patient characteristics and
treatment history are presented in Tables 1 and 2, respectively.
According to the Montreal classification of disease behaviour,
29% had luminal, 52% stricturing and 19% penetrating disease.
Approximately one third of patients had also perianal CD.
Of 48 patients, 46 (96%) had been treated with at least
one biologic drug before initiation of UST. Of these 46
patients, 34 (71%) had experienced two or three prior bio-
logic agents. Table 2 depicts drug treatment history of the
patients in more detail.
The most common reason to initiate UST treatment was
nonresponse to previous biologic treatment (90%). Other rea-
sons were side effects of prior biologic drugs (31%) or intol-
erability or inefficacy of immunomodulators (40%). In less
than 10% of patients the reported reasons for choosing UST
were psoriasis, cardiomyopathy, or unspecified contraindica-
tions to TNF-inhibitors.
Dosing and treatment persistence
UST intravenous induction dose was administered according
to the EU SmPC 6mg/kg in 130mg steps and mean UST
dose was 5.6mg/kg (SD 0.8). All 48 patients received at least
one 90mg subcutaneous dose of UST following the intraven-
ous induction. A vast majority (46 patients, 96%) received
the first subcutaneous dose 8 weeks after intravenous induc-
tion whereas the remaining two patients received that dose
12 weeks after the intravenous induction.
Figure 1. Map presenting study participants at represented hospital district in
Finland including the number of patients treated with ustekinumab.
Table 1. Baseline patient characteristics and phenotype.
Characteristic n Mean (SD)
Age, years 48 42.2 (14.9)
Weight (kg) 48 72.2 (21.6)
Heighta (cm) 40 170.5 (9.0)
Disease duration, years 48 13.9 (10.3)
n %
Gender, male 22 45.8
Smoking
Yes 14 29.2
No 29 60.4
Prior smoking 5 10.4
Prior CD-related surgery 30 62.5
Intestinal resections 25 83
Fistula/abscess operation 5 17
Montreal classification
Age at diagnosis
A1 9 18.8
A2 29 60.4
A3 10 20.8
Location
L1 or L1þ L4 10 20.8
L2 13 27.1
L3/ L3þ L4 or L4 21/4 43.8/8.3
Behaviour
B1 14 29.2
B2 25 52.1
B3 9 18.8
Perianal 16 33.3
Comorbiditiesb 6 12.5
aHeight: data for 40 patients available.
bAnkylosing spondylitis, psoriasis, hidradenitis suppurativa.
Table 2. Treatment history and concomitant drug use at baseline.
n %
Prior biologic treatment 46 95.8
Adalimumab 32 66.7
Infliximab 41 85.4
Vedolizumab 21 43.8
1 prior biologic 12 25.0
2 prior biologics 20 41.7
3 prior biologics 14 29.2
Concomitant drug treatment 35 72.9
Corticosteroids 23 47.9
Methotrexate 8 16.7
5-aminosalicylic acid 10 20.8
Thiopurines 8 16.7
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After induction with one intravenous and one subcutane-
ous UST dose, most patients (n¼ 42, 88%) continued UST
maintenance treatment (Figure 2). Of these 42 patients, 29
(69%) received UST 90mg subcutaneously every 8 weeks
and 13 (31%) 90mg subcutaneously every 12 weeks. Due to
insufficient response, 5 patients (12%) needed shortening of
the dosing interval either to 8, 6 or 4 weeks. This dose
adjustment occurred on average 8 months (median 5.5
months) after treatment initiation.
At the end of the follow-up, 40 patients (83%) persisted
on UST therapy (Figures 2 and 3). The reasons for discontinu-
ation of UST were lack of response, infection, pregnancy and
possible allergic reaction with unclear association to UST
(Figure 2).
All patients were followed for at least 16 weeks and were,
therefore, assessed at the 16 week timepoint. End of follow-
up data were available for 37 patients and 32 of them were
assessed at the end of follow-up based on continued
UST use.
Concomitant drugs
At baseline, 35 patients of 48 (73%), and at 16 weeks, 27
patients of 48 (56%) used concomitant drugs for treatment
of CD (Table 2, Figure 4). At the end of follow-up, concomi-
tant medication occurred in 15 patients of those 32 with
continued UST use (47%). Subsequently, the proportion of
patients receiving UST as monotherapy doubled from induc-
tion to the end of follow-up.
Importantly, after UST initiation the use of corticosteroids
decreased from 48% (23/48 patients) to 25% (12/48 patients)
in 16 weeks. By the end of follow-up, the use of corticoste-
roids in the study population had decreased significantly
(p¼ .001; 4/32 patients, 13%) and 88% of those patients con-
tinuing UST therapy were steroid-free (Figure 4).
Clinical effectiveness
Clinical outcome
Modified HBI decreased significantly from median of 9 (IQR
3–13; n¼ 35) at baseline to 3 (IQR 1–7) at 16 weeks (n¼ 24,
p¼ .0001) and to 4 (IQR 0–8) at the end of follow-up (n¼ 21,
p¼ .001; Table 3, Figure 5(b)).
At 16 weeks, 63% of patients (15/24), and at the end of
follow-up 52% (11/21 patients) were in clinical remission.
Furthermore, clinical response was achieved by 55% (12/22)
of patients at week 16 and by 60% (12/20) at the end of fol-
low-up. Clinical benefit, defined as either a response or
remission, was achieved by 83% (19/23) at week 16 and by
76% (16/21) at the end of follow-up (Figure 6).
Biological markers
The results of measured laboratory tests at baseline, around
16 weeks and at the end of the follow-up are presented in
Table 3. Compared to baseline, there was a statistically
Figure 2. Flow-chart of ustekinumab (UST) treatment in the FINUSTE study population. A total of 48 Crohn’s disease patients received intravenous (iv) UST treat-
ment at induction. Six patients (12.5%) lacked primary response or discontinued for other reasons. Forty-two patients (87.5%) continued UST treatment at 16
weeks. Two patients (4.2%) discontinued treatment due to lack of response after 16 weeks. Forty patients (83.3%) maintained UST at the end of follow-up, includ-
ing 5 UST dose intensified patients and 35 not intensified.
Figure 3. UST persistence (%) among Crohn’s disease patients presented in
Kaplan–Meier rates.
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significant decrease in median serum CRP at the end of fol-
low-up (Figure 5(d)). Furthermore, compared to baseline,
blood leukocyte count decreased significantly around 16
weeks. Modest changes in median fCal from baseline
(643lg/g; IQR 219–1390) to 16 weeks (472 lg/g; IQR
194–974) or end of follow up (561lg/g; IQR 118–1150) failed
to reach statistical significance (Table 3, Figure 5(c)).
Endoscopic healing
Endoscopic data and scoring of the SES-CD were available
for a small subgroup of study patients (at baseline n¼ 17, at
16 weeks n¼ 11, at the end of follow-up n¼ 6). The median
SES-CD decreased significantly from 12 (IQR 7–15) to 3 (IQR
0–6; p¼ .002) at 16 weeks. At the end of follow-up median
SES-CD was 3 (IQR 0–4), but this change could not show
statistical significance (p¼ .09, Table 3, Figure 5(a)).
Adverse events
During the study period four cases of potential adverse
events were reported. Half of them were mild (rash after
infusion, nonspecific pain in mouth), resolved spontaneously
and did not require UST withdrawal. In the remaining cases
UST treatment was discontinued (abscess formation, a pos-
sible allergic reaction with unclear association to UST).
Discussion
In the current study, we present data from a nationwide mul-
ticentre cohort that represents the real-life clinical practice in
the treatment of CD with UST in Finland. Patients had a
long-standing disease with a complex phenotype and the
most patients had failed several biological agents before ini-
tiation of UST. This highly treatment refractory cohort differs
from the patients included in the phase III UNITI trials, in
which the efficacy and safety of UST was demonstrated in
Figure 4. Concomitant drug use during ustekinumab treatment for Crohn’s disease (CD) at baseline, at 16 weeks, and at end of follow-up. Given are the total num-
ber of patients still using UST and the proportion of patients for the relevant CD treatment at specific time period. In parenthesis are the numbers of patients with
available data. Indicates statistically significant difference compared to baseline; p < .05.
Table 3. Clinical parameters during the study follow-up among UST users: median, (IQR, 25th–75th percentile).
Parameter
Baseline
n¼ 48
16 weeks
n¼ 48 p Value (vs. baseline)
End of follow-up
n¼ 32
p Value
(vs. baseline)
Haemoglobin, g/l 134 (120–143)
n¼ 48
133 (122–139)
n¼ 46
p¼ 0.84 138 (129–148)
n¼ 32
p¼ 0.43
Leukocytes, E9/l 8.6 (7.0–11.8)
n¼ 48
7.7 (5.7–10.4)
n¼ 46
p ¼ .003 7.5 (6.7–10.2)
n¼ 32
p ¼.07
Platelets, E9/l 334 (284–449)
n¼ 48
324 (297–427)
n¼ 45
p¼ 0.43 315 (267–400)
n¼ 32
p¼ 0.26
P-Albumin, g/l 33 (29–37)
n¼ 34
34 (29–36)
n¼ 32
p¼ 0.79 33 (29–36)
n¼ 13
p¼ 0.91
C-reactive protein, mg/l 11 (5–19)
n¼ 48
8 (2–15)
n¼ 46
p¼ 0.17 8 (4–14)
n¼ 30
p ¼.02
Faecal calprotectin, mg/g 643 (219–1390)
n¼ 37
472 (194–974)
n¼ 29
p¼ 0.48 561 (118–1150)
n¼ 19
p ¼.06
SES-CD 12 (7–15)
n¼ 17
3 (0–6)
n¼ 11
p ¼.009 3 (0–4)
n¼ 6
p ¼.09
mHBI 9 (3–13)
n¼ 35
3 (1–7)
n¼ 24
p ¼.0001 4 (0–8)
n¼ 21
p ¼.001
mHBI: modified Harvey–Bradshaw index; SES-CD: simple endoscopic score for Crohn’s disease.  ¼ statistically significant change from baseline. n ¼ number of
patients with available data.
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Figure 5. Box and whiskers plot showing upper-lower extreme and median changes in (a) the Simple Endoscopic Score for Crohn’s disease (SES-CD), (b) modified
Harvey–Bradshaw index (mHBI), (c) faecal calprotectin (fCal) and (d) C-reactive protein (CRP), at baseline, at 16 weeks and at end of follow-up of Crohn’s disease
patients treated with ustekinumab. In parenthesis are the numbers of patients with available data at each timepoint. Indicate statistically significant difference
compared to baseline; p < .05.
Figure 6. Proportion of ustekinumab treated Crohn’s disease patients with response, remission and clinical benefit at week 16 and at end of follow-up.
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patients with CD [5]. Although, inclusion criteria for the
UNITI-1 trial were nonresponse or unacceptable side-effects
to TNF-inhibitors, all patients in the UNITI-2 trial were either
bio-naïve or TNF-inhibitor experienced without failing, and in
the IM-UNITI maintenance treatment trial less than half (44%)
of the patients had a history of previous treatment with TNF-
inhibitors [5]. By contrast, the proportion of patients in our
study failing prior biologic treatments is similar to that in the
other real-life cohort studies [11–19].
The majority of patients in our study benefited from UST
treatment and continued therapy at the end of follow-up.
Several retrospective single- and multicentre cohort studies
have evaluated UST clinical efficacy in patients with CD but
with highly variable dosing regimens before the approval of
the current posology by EMA. Although, the administration
route of UST has mainly been subcutaneous, the reported
short-term clinical response rates in patients with CD have
been between 39% and 84% and medium- and long-term
rates between 60% and 78% [11–18]. Furthermore, treatment
persistence rates from 55% to 72% have been described in
these real-life cohorts [13,18]. In a recently published pro-
spective study using intravenous UST induction a clinical
response rate of 40% at week 24 was observed in patients
with CD [19]. We observed comparable results to these stud-
ies with an overall UST persistence rate of 83% at the end of
the follow-up and a clinical benefit in 76% of patients
achieving either clinical response and/or being in clin-
ical remission.
An important finding in our study was the significant
reduction in the use of corticosteroids after the initiation of
UST. At the end of follow-up, 88% of patients were steroid-
free. In previously published cohort studies of CD patients,
steroid-free remission rates vary largely from 25% to 95%,
which could be due to the heterogeneity of dosing regimens
and clinical endpoints [13,14,16,26,27].
Further, in the current study, a significant reduction of
endoscopic activity, measured by the validated SES-CD was
observed at week 16 in a subgroup of patients with available
endoscopic data. This is in line with the results of the endo-
scopic sub-study in the UNITI-studies, where mean SES-CD at
week 8 decreased by 2.8 points after a single UST infusion
and demonstrated an endoscopic response and remission
rate of 21% and 8%, respectively [7]. Other retrospective
cohort studies have evaluated UST efficacy on mucosal heal-
ing and reported endoscopic response and remission rates
between 55% and 82% and 20% and 39%, respectively
[13,14,16,18,26]. The only prospective real-life UST study to
date with intravenous induction reported an endoscopic
response rate of 21% and an endoscopic remission rate of
7% [19]. The median SES-CD in our study remained stable at
a low-level during the follow-up period, but a slight numer-
ical increase in fCal was measurable. However, neither the
SES-CD decrease at the end of follow-up nor the changes in
fCal reached statistically significance.
The safety of UST treatment as measured by the number
and severity of reported adverse events in our study resem-
bles the good safety profile of UST observed in the clinical
trials and other cohort studies both in patients with CD and
those with psoriasis [5,12–19,28]. Concomitant immunomo-
dulators and corticosteroids can increase the risk of adverse
events, especially infections [2]. Recent data suggest that
UST can be used as monotherapy as concurrent use of
immunomodulators do not seem to effect immunogenity or
remission efficacy of UST [29,30].
A major strength of this study is the nationwide inclusion
of hospitals, covering almost all centres in Finland adminis-
trating UST intravenous induction during 2017. Also, a wide
variety of collected data such as demographic factors,
comorbidities, previous and concomitant CD medication, as
well as biomarkers, were included in the study. Among the
limitations of this study are the small patient number and
incomplete data of the SES-CD, mHBI and fCal due to the
retrospective design. Further limitations are the lack of data
in UST trough levels or anti-drug antibodies and the missing
information of UST efficacy on fistula healing.
In conclusion, the current real-life study presents evidence
that UST is an effective treatment option in CD patients who
have previously failed even several other biologic agents.
Currently in Finland, UST is mainly used as a second- or
third-line biologic medication for CD patients. Emerging data
from real-life studies together with the increasing clinical
experience with UST will probably influence treatment algo-
rithms for CD in the future. In further studies, the potential
benefit of UST dose-optimisation for mucosal healing needs
to be evaluated.
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